title: Ebselen effects on MPTP-induced neurotoxicity.
abstract: We evaluated the effect of ebselen on human SH-SY5Y dopaminergic neuronal cells and determined whether ebselen, a glutathione peroxidase-mimetic, protected against MPTP-induced dopamine depletion in mice. Ebselen (10-100 microM) inhibited the proliferation of SH-SY5Y cells dose-dependently. Ebselen did not induce any behavioral changes and did not block MPTP-induced tremor and akinesia. Ebselen had no effect on the monoamine oxidase activity and did not protect against MPTP-induced dopamine depletion in striatum.
authors.affiliation: Department of Pharmacal Sciences, Division of Pharmacology and Toxicology, Harrison School of Pharmacy, Auburn University, Auburn, AL 36849, USA. dhanamu@auburn.edu
authors.forename: Muralikrishnan
authors.initials: M
authors.lastname: Dhanasekaran
authors.forename: Subramaniam
authors.initials: S
authors.lastname: Uthayathas
authors.forename: Senthilkumar S
authors.initials: SS
authors.lastname: Karuppagounder
authors.forename: Kodeeswaran
authors.initials: K
authors.lastname: Parameshwaran
authors.forename: Vishnu
authors.initials: V
authors.lastname: Suppiramaniam
authors.forename: Manuchair
authors.initials: M
authors.lastname: Ebadi
authors.forename: Holly M
authors.initials: HM
authors.lastname: Brown-Borg
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000037:antagonists & inhibitors; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D001393:Azoles / Q000494:pharmacology* / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005979:Glutathione Peroxidase / Q000378:metabolism; D006801:Humans; D054833:Isoindoles; D051379:Mice; D008810:Mice, Inbred C57BL; D008995:Monoamine Oxidase / Q000187:drug effects / Q000378:metabolism; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology*; D016566:Organoselenium Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D020734:Parkinsonian Disorders / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D016896:Treatment Outcome; D014202:Tremor / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology
chemical_list: D000975:Antioxidants; D001393:Azoles; D054833:Isoindoles; D018696:Neuroprotective Agents; D016566:Organoselenium Compounds; C042986:ebselen; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D005979:Glutathione Peroxidase; D008995:Monoamine Oxidase; D004298:Dopamine